Avodart vs Dutas T: Dutasteride Brand vs WHO-GMP Combination Compared

✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

Dutasteride is the more potent of the two clinically available 5α-reductase inhibitors. Whereas finasteride selectively blocks type II 5α-reductase (the dominant isoenzyme in scalp and prostate), dutasteride blocks both type I and type II isoenzymes — suppressing approximately 95% of circulating DHT versus finasteride’s ~70%, and approximately 95% of scalp DHT versus finasteride’s ~60%. This translates clinically to stronger hair-regrowth response in non-responders to finasteride, more reliable prostate-volume reduction, and a somewhat higher rate of the sexual side effects characteristic of the 5α-reductase inhibitor class.

GSK obtained FDA approval for Avodart (dutasteride 0.5 mg) in November 2001 for symptomatic benign prostatic hyperplasia. The hair-loss application was studied in the Jung et al. and Eun et al. trials¹² but is not FDA-approved — dutasteride for hair loss is off-label in the US, though approved on-label in South Korea, Japan, and several other markets.

GSK’s US dutasteride patent expired in 2015 and generic Avodart entered US retail pharmacies that year. The dual-inhibitor mechanism’s stronger DHT suppression and clinical response have made dutasteride the standard escalation step for men with androgenetic alopecia who haven’t responded adequately to finasteride 1 mg.

TL;DR comparison table

Why dutasteride is more potent than finasteride

The 5α-reductase enzyme exists as two clinically relevant isoenzymes:

• Type I: expressed primarily in liver, skin, and sebaceous glands.
• Type II: dominant in prostate, scalp, hair follicles, and external genitalia.

Finasteride selectively inhibits type II at therapeutic doses (1 mg for hair, 5 mg for BPH). Dutasteride inhibits both type I and type II at the 0.5 mg dose. The clinical consequence:

• Circulating DHT suppression: dutasteride ~95% vs finasteride ~70%.
• Scalp DHT suppression: dutasteride ~95% vs finasteride ~60%.
• Hair count improvement at 24 weeks: dutasteride 0.5 mg approximately 15–20% greater than finasteride 1 mg in head-to-head trials.¹
• Prostate volume reduction: dutasteride 0.5 mg approximately equivalent to finasteride 5 mg over 24 months.

The stronger pharmacological effect comes with a slightly higher rate of the sexual side effects that characterise the 5α-reductase inhibitor class. Rates remain low in absolute terms but are roughly 1.5× finasteride at the same comparator endpoints.

The dutasteride + tamsulosin combination logic

Benign prostatic hyperplasia produces lower urinary tract symptoms via two mechanisms: static (structural) compression of the urethra by enlarged prostate tissue, and dynamic (smooth-muscle) tone of the bladder neck and prostatic urethra. Each is addressed by a different drug class:

• 5α-reductase inhibitors (dutasteride, finasteride) — reduce prostate volume over months. Addresses the static component.
• Alpha-1 blockers (tamsulosin, alfuzosin, terazosin) — relax bladder neck and prostatic smooth muscle within days. Addresses the dynamic component.

Combining the two produces immediate symptom relief (tamsulosin within 1–2 weeks) with progressive structural improvement (dutasteride over 6–12 months). This combination was studied formally in the CombAT trial (Roehrborn et al., European Urology, 2010³), which demonstrated superior symptom outcomes and reduced risk of clinical BPH progression (acute urinary retention or BPH-related surgery) versus either monotherapy.

GSK’s Jalyn (the FDA-approved Avodart + tamsulosin combination tablet) followed in 2010. Dutas T from WHO-GMP-certified manufacturers is the corresponding generic combination product.

Bioequivalence and Dutas T positioning

Dutas T contains dutasteride 0.5 mg + tamsulosin 0.4 mg in a single tablet — the same active-ingredient composition as Jalyn. The molecule and pharmacology are identical between branded Jalyn and Dutas T. Dutas T is manufactured under WHO-GMP standards. The MedsBase product page is /dutas-t/.

For hair-loss-only use, where the alpha-blocker is not needed, the standard approach is dutasteride 0.5 mg monotherapy. MedsBase does not currently stock the standalone Dutas 0.5 mg product; Dutas T is the available format. Some hair-loss users take the combination tablet anyway and tolerate the tamsulosin effect (which is generally minimal in younger men without prostate issues), but the technically appropriate path for hair-loss-only indication is standalone dutasteride from a different supplier.

Price comparison

Side effects

The dutasteride side-effect profile is similar to finasteride but with slightly higher rates for the class effects:¹

• Decreased libido (~3–4%, higher than finasteride’s 1.8%)
• Erectile dysfunction (~5%, higher than finasteride’s 1.3%)
• Decreased ejaculate volume (~1–2%)
• Gynaecomastia or breast tenderness (~1%)
• Depressed mood (signal, magnitude debated)

The Dutas T combination adds tamsulosin-specific effects:

• Orthostatic hypotension — dizziness on standing, particularly first dose. Take first dose at bedtime.
• Retrograde ejaculation — ~4–8%; semen enters bladder rather than emerging. Not harmful, but affects fertility plans.
• Rhinitis (~5%)

The post-finasteride-syndrome (PFS) discussion applies equally to dutasteride. The mechanism (5α-reductase inhibition) is the same; persistent post-discontinuation sexual symptoms have been described for both finasteride and dutasteride at similar rates. See our Propecia vs Finpecia guide for the PFS context.

Contraindications

Manufacturer disclosure

Dutas T is manufactured under WHO-GMP certification per the same quality framework applied across MedsBase’s generic-medication lines (HPLC content uniformity for both active ingredients, dissolution testing per USP, stability monitoring per ICH). Certificates of Analysis are available on request through MedsBase customer support — provide order ID and the batch number from your blister.

How to order from MedsBase

Dutas T ships worldwide from MedsBase in discreet packaging. Payment via crypto (Plisio), credit card via a regulated crypto on-ramp, or SEPA. See our credit card payment guide. Orders are covered by the MedsBase Reshipment Assurance Policy.

Who should choose dutasteride over finasteride?

• Finasteride non-responders or partial responders — men who have used finasteride 1 mg for 12+ months without adequate hair regrowth are appropriate candidates for dutasteride escalation. The mechanism rationale is the stronger DHT suppression from dual-isoenzyme inhibition.
• BPH with prostate volume >40 mL — dutasteride is the preferred 5α-reductase inhibitor for symptomatic BPH with established prostate enlargement. Combined with tamsulosin (Dutas T) for immediate symptom relief plus structural improvement.
• Combined BPH + early hair loss — one tablet addresses both. Dutas T treats prostate symptoms and as a class-effect reduces scalp DHT.
• NOT first-line for hair loss alone: for men starting hair-loss treatment, finasteride 1 mg (Finpecia) is the standard first choice. Dutasteride is the escalation step, not the starting point.

For combined finasteride + minoxidil hair-loss therapy, see Propecia vs Finpecia and Rogaine vs Tugain. The MedsBase Hair Loss Stack bundles finasteride + minoxidil for first-line therapy.

Pricing context: The brand-vs-generic price comparison on this page is one entry in MedsBase’s broader Brand-vs-Generic Medication Pricing Index — a quarterly-updated reference covering 15 brand-vs-generic pairs across ED, GLP-1, hair-loss, PrEP, and cosmetic clusters, with full methodology and citation disclosure.

Frequently Asked Questions

Is dutasteride better than finasteride for hair loss?

For most men with mild-to-moderate androgenetic alopecia, finasteride 1 mg is the standard first-line choice and produces meaningful improvement in ~80–90% of users. Dutasteride is the escalation step for men who don’t respond adequately to finasteride after 12 months — it suppresses DHT more completely (95% vs 60% in scalp) and produces incremental hair improvement in many non-responders. The sexual side-effect rate is slightly higher.

What is Dutas T, and how is it different from pure Avodart?

Dutas T is a combination tablet containing dutasteride 0.5 mg + tamsulosin 0.4 mg. Avodart is dutasteride alone. The combination is specifically for symptomatic BPH (both immediate symptom relief from tamsulosin and structural improvement from dutasteride). The FDA-approved equivalent of Dutas T is GSK’s Jalyn.

Can I take Dutas T just for hair loss?

The tamsulosin component is not necessary for hair-loss treatment and adds potential side effects (orthostatic hypotension, retrograde ejaculation). For hair-loss-only indication, standalone dutasteride 0.5 mg is the technically appropriate format. MedsBase currently stocks the Dutas T combination format; for pure dutasteride, the FDA-approved US generic supply is the standard source.

What about the long half-life?

Dutasteride’s plasma half-life is approximately 5 weeks — much longer than finasteride’s 6–8 hours. The clinical consequence is that the drug stays in your system for months after discontinuation, and adverse effects (if they develop) take longer to resolve. Plan ahead for any need to discontinue: at least 6 months for plasma levels to fall below detection.

Is Dutas T safe long-term?

Dutasteride has a 20+ year post-market safety record. The CombAT trial established 4-year safety data for the combination with tamsulosin. The principal long-term concerns are class-effect sexual side effects and the high-grade prostate cancer signal from REDUCE trial data (clinical relevance debated). For most men with appropriate indications, the risk-benefit calculation is favourable.

How does the PSA effect work?

Dutasteride approximately halves baseline PSA over 6–12 months. For prostate cancer screening, your prescriber needs to know you take dutasteride to interpret PSA values — reported values must be doubled for comparison to the standard reference range. Any rising PSA on dutasteride is especially concerning because the drug should be holding PSA down.

What about the post-finasteride-syndrome (PFS) discussion?

The PFS controversy applies equally to dutasteride. The mechanism (5α-reductase inhibition) is the same; persistent post-discontinuation sexual symptoms have been described in case-report and patient-advocacy literature for both molecules at similar rates. If sexual side effects develop, discontinue the drug rather than persisting through them. See our finasteride guide for the full PFS context.

How is Dutas T so much cheaper than Avodart or Jalyn?

Patent expiry on dutasteride in 2015 enabled generic competition globally. WHO-GMP manufacturing produces dutasteride and tamsulosin at substantially lower cost than the original branded supply chains. Dutas T benefits from the additional savings of a single-tablet combination format eliminating separate dispensing of two pills.

Sources

1. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride vs finasteride. Journal of the American Academy of Dermatology. 2006;55(6):1014–1023.
2. Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. Journal of the American Academy of Dermatology. 2010;63(2):252–258.
3. Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. European Urology. 2010;57(1):123–131.
4. US Food and Drug Administration. NDA 021319, Avodart (dutasteride). Approval letter, 20 November 2001.
5. US Food and Drug Administration. NDA 022460, Jalyn (dutasteride/tamsulosin). Approval letter, 14 June 2010.

Last clinically reviewed: 18 May 2026.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.